Optic Neuritis Following the BNT162b2 mRNA COVID-19 Vaccine in a Patient with Systemic Lupus Erythematosus Uncovering the Diagnosis of Neuromyelitis Optica Spectrum Disorders

Ocul Immunol Inflamm. 2023 Aug;31(6):1213-1215. doi: 10.1080/09273948.2022.2089901. Epub 2022 Jul 18.

Abstract

COVID-19 vaccinations have been given worldwide to save the lives of millions. However, several complications following different types of COVID-19 vaccinations were reported previously in the literature. Previous articles have reported multiple ocular complications following different types of COVID-19 vaccinations. In this article, we report a unique case in which the diagnosis of neuromyelitis optica spectrum disorders (NMOSD) was unveiled following vaccination with BNT162b2 mRNA COVID-19 vaccine and manifesting as acute optic neuritis in a patient with systemic lupus erythematosus (SLE). The temporal association of acute optic neuritis after receiving the BNT162b2 mRNA COVID-19 vaccine along with the serological evidence of NMOSD support this theory. The risk of triggering an occult autoimmune disorder in patients with an overactive immune system such as this patient should be studied to calibrate the benefits and risks of vaccination against COVID-19. Screening for aquaporin-4 antibodies in patients with SLE prior to vaccination against COVID-19 may be considered to prevent potentially devastating neurological disability in patients with premorbid occult NMOSD.

Keywords: BNT162b2 mRNA; COVID-19; neuromyelitis optica spectrum disorders; optic neuritis; systemic lupus erythematosus; vaccine.

Publication types

  • Case Reports

MeSH terms

  • Autoantibodies
  • BNT162 Vaccine
  • COVID-19 Testing
  • COVID-19 Vaccines / adverse effects
  • COVID-19* / complications
  • COVID-19* / diagnosis
  • Humans
  • Lupus Erythematosus, Systemic* / complications
  • Lupus Erythematosus, Systemic* / diagnosis
  • Neuromyelitis Optica* / complications
  • Neuromyelitis Optica* / etiology
  • Optic Neuritis* / diagnosis

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • Autoantibodies